The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acute Intermittent Porphyria Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
The global Acute Intermittent Porphyria Drugs market size is expected to reach US$ 56 million by 2029, growing at a CAGR of 1.8% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Intermittent Porphyria Drugs in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Acute Intermittent Porphyria Drugs market. 350mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 313mg segment is estimated at % CAGR for the next seven-year period.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Intermittent Porphyria Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Intermittent Porphyria Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Intermittent Porphyria Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Intermittent Porphyria Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Intermittent Porphyria Drugs covered in this report include Recordati Rare Diseases. etc.
The global Acute Intermittent Porphyria Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Recordati Rare Diseases
Global Acute Intermittent Porphyria Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Intermittent Porphyria Drugs market, Segment by Type:
350mg
313mg
Global Acute Intermittent Porphyria Drugs market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Acute Intermittent Porphyria Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Acute Intermittent Porphyria Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
The global Acute Intermittent Porphyria Drugs market size is expected to reach US$ 56 million by 2029, growing at a CAGR of 1.8% from 2023 to 2029. The market is mainly driven by the significant applications of Acute Intermittent Porphyria Drugs in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Acute Intermittent Porphyria Drugs market. 350mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 313mg segment is estimated at % CAGR for the next seven-year period.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acute Intermittent Porphyria Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acute Intermittent Porphyria Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acute Intermittent Porphyria Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acute Intermittent Porphyria Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acute Intermittent Porphyria Drugs covered in this report include Recordati Rare Diseases. etc.
The global Acute Intermittent Porphyria Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Recordati Rare Diseases
Global Acute Intermittent Porphyria Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Intermittent Porphyria Drugs market, Segment by Type:
350mg
313mg
Global Acute Intermittent Porphyria Drugs market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Acute Intermittent Porphyria Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Acute Intermittent Porphyria Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Acute Intermittent Porphyria Drugs Market Overview
1.1 Acute Intermittent Porphyria Drugs Product Overview
1.2 Acute Intermittent Porphyria Drugs Market Segment by Type
1.2.1 350mg
1.2.2 313mg
1.3 Global Acute Intermittent Porphyria Drugs Market Size by Type
1.3.1 Global Acute Intermittent Porphyria Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Acute Intermittent Porphyria Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Acute Intermittent Porphyria Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Acute Intermittent Porphyria Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Acute Intermittent Porphyria Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Acute Intermittent Porphyria Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Acute Intermittent Porphyria Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Acute Intermittent Porphyria Drugs Sales Breakdown by Type (2018-2023)
2 Global Acute Intermittent Porphyria Drugs Market Competition by Company
2.1 Global Top Players by Acute Intermittent Porphyria Drugs Sales (2018-2023)
2.2 Global Top Players by Acute Intermittent Porphyria Drugs Revenue (2018-2023)
2.3 Global Top Players by Acute Intermittent Porphyria Drugs Price (2018-2023)
2.4 Global Top Manufacturers Acute Intermittent Porphyria Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Acute Intermittent Porphyria Drugs Market Competitive Situation and Trends
2.5.1 Acute Intermittent Porphyria Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Acute Intermittent Porphyria Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acute Intermittent Porphyria Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Acute Intermittent Porphyria Drugs Market
2.8 Key Manufacturers Acute Intermittent Porphyria Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Acute Intermittent Porphyria Drugs Status and Outlook by Region
3.1 Global Acute Intermittent Porphyria Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Acute Intermittent Porphyria Drugs Historic Market Size by Region
3.2.1 Global Acute Intermittent Porphyria Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Acute Intermittent Porphyria Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Acute Intermittent Porphyria Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Acute Intermittent Porphyria Drugs Forecasted Market Size by Region
3.3.1 Global Acute Intermittent Porphyria Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Acute Intermittent Porphyria Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Acute Intermittent Porphyria Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Acute Intermittent Porphyria Drugs by Application
4.1 Acute Intermittent Porphyria Drugs Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.2 Global Acute Intermittent Porphyria Drugs Market Size by Application
4.2.1 Global Acute Intermittent Porphyria Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Acute Intermittent Porphyria Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Acute Intermittent Porphyria Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Acute Intermittent Porphyria Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Acute Intermittent Porphyria Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Acute Intermittent Porphyria Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Acute Intermittent Porphyria Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Acute Intermittent Porphyria Drugs Sales Breakdown by Application (2018-2023)
5 North America Acute Intermittent Porphyria Drugs by Country
5.1 North America Acute Intermittent Porphyria Drugs Historic Market Size by Country
5.1.1 North America Acute Intermittent Porphyria Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Acute Intermittent Porphyria Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Acute Intermittent Porphyria Drugs Sales in Value by Country (2018-2023)
5.2 North America Acute Intermittent Porphyria Drugs Forecasted Market Size by Country
5.2.1 North America Acute Intermittent Porphyria Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Acute Intermittent Porphyria Drugs Sales in Value by Country (2024-2029)
6 Europe Acute Intermittent Porphyria Drugs by Country
6.1 Europe Acute Intermittent Porphyria Drugs Historic Market Size by Country
6.1.1 Europe Acute Intermittent Porphyria Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Acute Intermittent Porphyria Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Acute Intermittent Porphyria Drugs Sales in Value by Country (2018-2023)
6.2 Europe Acute Intermittent Porphyria Drugs Forecasted Market Size by Country
6.2.1 Europe Acute Intermittent Porphyria Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Acute Intermittent Porphyria Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Acute Intermittent Porphyria Drugs by Region
7.1 Asia-Pacific Acute Intermittent Porphyria Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Acute Intermittent Porphyria Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Acute Intermittent Porphyria Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Acute Intermittent Porphyria Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Acute Intermittent Porphyria Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Acute Intermittent Porphyria Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Acute Intermittent Porphyria Drugs Sales in Value by Region (2024-2029)
8 Latin America Acute Intermittent Porphyria Drugs by Country
8.1 Latin America Acute Intermittent Porphyria Drugs Historic Market Size by Country
8.1.1 Latin America Acute Intermittent Porphyria Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Acute Intermittent Porphyria Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Acute Intermittent Porphyria Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Acute Intermittent Porphyria Drugs Forecasted Market Size by Country
8.2.1 Latin America Acute Intermittent Porphyria Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Acute Intermittent Porphyria Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Acute Intermittent Porphyria Drugs by Country
9.1 Middle East and Africa Acute Intermittent Porphyria Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Acute Intermittent Porphyria Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Acute Intermittent Porphyria Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Acute Intermittent Porphyria Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Acute Intermittent Porphyria Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Acute Intermittent Porphyria Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Acute Intermittent Porphyria Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Recordati Rare Diseases
10.1.1 Recordati Rare Diseases Company Information
10.1.2 Recordati Rare Diseases Introduction and Business Overview
10.1.3 Recordati Rare Diseases Acute Intermittent Porphyria Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Recordati Rare Diseases Acute Intermittent Porphyria Drugs Products Offered
10.1.5 Recordati Rare Diseases Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Acute Intermittent Porphyria Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Acute Intermittent Porphyria Drugs Industrial Chain Analysis
11.4 Acute Intermittent Porphyria Drugs Market Dynamics
11.4.1 Acute Intermittent Porphyria Drugs Industry Trends
11.4.2 Acute Intermittent Porphyria Drugs Market Drivers
11.4.3 Acute Intermittent Porphyria Drugs Market Challenges
11.4.4 Acute Intermittent Porphyria Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Acute Intermittent Porphyria Drugs Distributors
12.3 Acute Intermittent Porphyria Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
